ArticleCardiology and therapy2025
Incidence and Healthcare Resource Utilization Among Patients with Hypertrophic Cardiomyopathy Hospitalized for Heart Failure in Japan.
Article in Cardiology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure (HF) is one of the most common complications in patients with hypertrophic cardiomyopathy (HCM); however, there are limited data on HCM burden in Japan. We evaluated the burden of HF hospitalization and factors that predispose patients with HCM to HF hospitalization.
methodsThis retrospective observational database study used a hospital-based claims database from January 01, 2011, to December 31, 2023, provided by Medical Data Vision Co., Ltd. The primary objective of the study was to calculate the incidence of first HF hospitalization after HCM diagnosis. A nested case-control design compared patients with or without hospitalization to identify factors associated with HF hospitalization. Hospitalization costs and outcomes after discharge were also described.
resultsOf 12,145 patients with newly diagnosed HCM without HF hospitalization, 525 were hospitalized with HF during the follow-up period. The mean age ± standard deviation (SD) of the overall study population at cohort entry date was 71.4 ± 14.0 years, and 45.8% were female patients. The incidence of HF hospitalization was 17.2 events/1000 patient-years. Patients with HCM hospitalized for HF had higher rates of comorbidities, including HF (45.9%), diabetes mellitus (28.6%), hypertension (23.0%), atrial fibrillation (AF; 21.3%), myocardial infarction (MI; 17.5%), arrhythmia except AF (15.0%), and dyslipidemia (13.1%), than patients without HF hospitalization. Significant predictors of hospitalization among patients with HCM were AF (odds ratio [OR] 1.63; 95% confidence interval [CI] 1.18-2.25; p = 0.003), MI (OR 1.68; 95% CI 1.20-2.35; p = 0.003), HF (OR 1.82; 95% CI 1.39-2.39; p < 0.001), chronic obstructive pulmonary disease (OR 2.30; 95% CI 1.08-4.89; p = 0.031), and loop diuretics (OR 4.35; 95% CI 3.33-5.69; p < 0.001). The average costs, length of hospital stay, and overall mortality rate associated with HF hospitalization were 1035 kJPY (~ 156,750 USD), 20.0 days, and 8.8%, respectively.
conclusionsHF hospitalization in patients with HCM imposes a significant clinical and economic burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.